Actively Recruiting
Phase 2 Study of PRGN-2009 with Pembrolizumab for Treating Recurrent or Metastatic Cervical Cancer Resistant to Pembrolizumab
Led by Precigen, Inc · Updated on 2026-04-23
24
Participants Needed
3
Research Sites
211 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of PRGN-2009 combined with pembrolizumab in patients with recurrent or metastatic cervical cancer who have not responded to pembrolizumab alone. This Phase 2 study focuses on patients with pembrolizumab-resistant cervical cancer confirmed by tissue tests and positive for HPV. The study aims to better understand how this combination treatment affects tumor response and overall patient outcomes. Participants will receive PRGN-2009 through a subcutaneous injection at a dose of 5 x 1011 PU every three weeks for the first three doses, then every six weeks thereafter. Pembrolizumab will be given intravenously at 400 mg every six weeks alongside PRGN-2009. This treatment schedule continues throughout the study period, with no placebo group, to assess the combined therapys impact on cervical cancer. Throughout the study, participants will undergo regular evaluations including scans to measure tumor size according to RECIST v1.1 criteria, laboratory tests to monitor organ function, and assessments of overall health and side effects. Researchers will track the objective response rate, progression-free survival, and overall survival over one year. Additional monitoring includes checking for vector shedding after PRGN-2009 administration up to four months. The total study duration extends until November 2030, ensuring thorough safety and effectiveness data collection.
CONDITIONS
Brief Title
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Research Team
A
Amy Lankford
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here